135 related articles for article (PubMed ID: 15197616)
1. Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells.
Jeremias I; Steiner HH; Benner A; Debatin KM; Herold-Mende C
Acta Neurochir (Wien); 2004 Jul; 146(7):721-9. PubMed ID: 15197616
[TBL] [Abstract][Full Text] [Related]
2. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
3. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells.
Fulda S; Jeremias I; Debatin KM
Oncogene; 2004 Oct; 23(46):7611-20. PubMed ID: 15361826
[TBL] [Abstract][Full Text] [Related]
4. Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein.
Voelkel-Johnson C; Hannun YA; El-Zawahry A
Mol Cancer Ther; 2005 Sep; 4(9):1320-7. PubMed ID: 16170023
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors.
Kasuga C; Ebata T; Kayagaki N; Yagita H; Hishii M; Arai H; Sato K; Okumura K
Cancer Sci; 2004 Oct; 95(10):840-4. PubMed ID: 15504253
[TBL] [Abstract][Full Text] [Related]
7. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.
Panner A; James CD; Berger MS; Pieper RO
Mol Cell Biol; 2005 Oct; 25(20):8809-23. PubMed ID: 16199861
[TBL] [Abstract][Full Text] [Related]
8. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
Redjal N; Zhu Y; Shah K
Stem Cells; 2015 Jan; 33(1):101-10. PubMed ID: 25186100
[TBL] [Abstract][Full Text] [Related]
9. Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.
Xu Y; Li J; Li QJ; Feng YL; Pan F
Biomed Pharmacother; 2017 Apr; 88():349-358. PubMed ID: 28119237
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
Murphy ÁC; Weyhenmeyer B; Noonan J; Kilbride SM; Schimansky S; Loh KP; Kögel D; Letai AG; Prehn JH; Murphy BM
Apoptosis; 2014 Apr; 19(4):629-42. PubMed ID: 24213561
[TBL] [Abstract][Full Text] [Related]
11. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
12. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
13. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
[TBL] [Abstract][Full Text] [Related]
14. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells.
Cantarella G; Risuglia N; Dell'eva R; Lempereur L; Albini A; Pennisi G; Scoto GM; Noonan DN; Bernardini R
Br J Cancer; 2006 May; 94(10):1428-35. PubMed ID: 16622457
[TBL] [Abstract][Full Text] [Related]
15. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
Martin S; Phillips DC; Szekely-Szucs K; Elghazi L; Desmots F; Houghton JA
Cancer Res; 2005 Dec; 65(24):11447-58. PubMed ID: 16357153
[TBL] [Abstract][Full Text] [Related]
17. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
18. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200
[TBL] [Abstract][Full Text] [Related]
19. Overcoming TRAIL Resistance for Glioblastoma Treatment.
Deng L; Zhai X; Liang P; Cui H
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33919846
[TBL] [Abstract][Full Text] [Related]
20. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines.
Siervo-Sassi RR; Marrangoni AM; Feng X; Naoumova N; Winans M; Edwards RP; Lokshin A
Cancer Lett; 2003 Feb; 190(1):61-72. PubMed ID: 12536078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
